Werendi 13,3 mg/24 Stunden Transdermales Pflaster Saksa - saksa - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

werendi 13,3 mg/24 stunden transdermales pflaster

luye pharma ag (8028156) - rivastigmin - transdermales pflaster - 13,3 mg/24 stunden - teil 1 - transdermales pflaster; rivastigmin (23590) 19,2 milligramm

Werendi 4,6 mg/24 Stunden Transdermales Pflaster Saksa - saksa - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

werendi 4,6 mg/24 stunden transdermales pflaster

luye pharma ag (8028156) - rivastigmin - transdermales pflaster - 4,6 mg/24 stunden - teil 1 - transdermales pflaster; rivastigmin (23590) 6,4 milligramm

Werendi 9,5 mg/24 Stunden Transdermales Pflaster Saksa - saksa - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

werendi 9,5 mg/24 stunden transdermales pflaster

luye pharma ag (8028156) - rivastigmin - transdermales pflaster - 9,5 mg/24 stunden - teil 1 - transdermales pflaster; rivastigmin (23590) 12,8 milligramm

Pylclari Euroopan unioni - saksa - EMA (European Medicines Agency)

pylclari

curium pet france - piflufolastat (18f) - prostata-neoplasmen - diagnostische radiopharmaka - dieses arzneimittel ist nur für diagnostische zwecke bestimmt. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).